12/04/2012 - Press release
The study has been published in the prestigious journal Molecular Cell
Researchers at the Hospital de Mar Research Institute (IMIM) have discovered that the protein LOXL2 has a function within the cell nucleus thus far unknown. They have also described a new chemical reaction of this protein on histone H3 that would be involved in gene silencing, one of which would be involved in the progression of breast, larynx, lung and skin tumours.
Led by Dr Sandra Peiró and published in Molecular Cell journal, the study is a significant advance in describing the evolution of tumours and opens the door to researching new treatments that block their activity. “LOXL2’s action on the intra-cellular level and its interaction with histone H3 stimulates tumour growth. The fact that the protein LOXL2 is an enzyme and is overly expressed in many types of cancer makes it a very good therapeutic target. Now that we know how it acts, we need to keep working to develop chemical inhibitors that counteract its activity”, the researcher explained.
Previous studies had identified the extra-cellular function of the protein LOXL2, and it was being studied as a possible therapeutic target for avoiding metastasis in certain kinds of tumours. However, this study has described the presence of this protein at the level of the cell nucleus for the first time.
The process of gene expression in cells consists of transforming the information of the DNA into the proteins necessary to carry out different functions. The DNA molecule has been found to form a certain structure due to its interaction with some proteins called histones. When these histones are modified, the structure of the DNA is also modified and the final result is the expression or non-expression of a certain group of genes.
In the case of tumour cells, the protein LOXL2 acts upon one of these histones (histone H3) and modifies it, eliminating the lysine 4 amino group, a change never described before. As a result of its action, the genes modulated by histone H3, modified by LOXL2, stop expression, preventing the cells from behaving normally and favouring tumour development.
The work of Sandra Peiró’s team is the conclusion of three years of effort focused on the biochemical characterisation of the protein LOXL2 and the study of its role in the modification of histone H3. Since this modification had never been described before, the data obtained open many lines of research. The location on the genomic level of the protein LOXL2 and histone H3, modified by LOXL2, and the possible existence of some enzyme that might neutralise its function, are two of the questions that the group aims to tackle in the years to come.
“Lysyl Oxidase-Like 2 (LOXL2) deaminates lysine 4 in Histone H3” Nicolás Herranz, Natàlia Dave, Alba Millanes-Romera, Lluís Morey, Víctor M. Díaz, Víctor Lórenz-Fonfría, Ricardo Gutierrez-Gallego, Celia Jerónimo, Luciano Di Croce, Antonio García de Herreros, Sandra Peiró. MOLECULAR-CELL-D-11-01044R3.
Document d'origen: Nou avanç en el coneixement de la progressió del càncer (Nota de premsa)
Número total d'impactes: 37
Número d'impactes classificat per tipus de mitjà:
A continuació us detallem els diferents impactes mediàtics:
12/04/2012 - Asturias mundial
12/04/2012 - Bioportfolio
12/04/2012 - Breakthrough Digest Medical News
12/04/2012 - Daily Me
12/04/2012 - eScience news
12/04/2012 - Gran Canaria Actualidad
12/04/2012 - GZZT
12/04/2012 - Health canal
12/04/2012 - Medical Xpress
12/04/2012 - Noticias de Biología
12/04/2012 - Plataforma SINC
12/04/2012 - PRBB.net
12/04/2012 - Science Codex
12/04/2012 - Science Daily
12/04/2012 - Science Newsline Biology
12/04/2012 - Tendencias Cientificas
12/04/2012 - ThunderFeeds
12/04/2012 - Noticies Parc de Salut Mar
12/04/2012 - Labslink
12/04/2012 - On examination
12/04/2012 - P Phosphorus
12/04/2012 - The cancer and oncology daily
13/04/2012 - Oncology Journal
13/04/2012 - PCOM Library (Philadelphia College of Osteopathic Medicine)
13/04/2012 - Diari Segre
14/04/2012 - BIOON News
15/04/2012 - Medical News Today
16/04/2012 - Diario Médico
16/04/2012 - News Medical
16/04/2012 - Gaceta Médica
16/04/2012 - Biotech Mashup
16/04/2012 - Cancer Evolution
16/04/2012 - Clinical laboratory
16/04/2012 - Gaceta Médica
16/04/2012 - Lysine
19/04/2012 - ESMO (European Society for Medical Oncology)
04/02/2013 - Diario el siglo